title: The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis.
abstract: OBJECTIVE
  To determine whether the presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies at presentation is of prognostic value in patients with palindromic arthritis.
  
  
  METHODS
  Stored sera, taken around the time of presentation from patients with palindromic arthritis, where available, were assessed for anti-CCP antibodies, and results were correlated with subsequent clinical outcome.
  
  
  RESULTS
  Twenty-nine of 61 patients had progressed to rheumatoid arthritis after a mean followup of 5.4 years; 83% of these had had anti-CCP antibodies in their baseline sera.
  
  
  CONCLUSIONS
  The sensitivity/specificity and likelihood ratios for CCP antibodies were better than rheumatoid factor in predicting outcome.
authors.affiliation: Department of Medicine, Division of Rheumatology, University of Alberta, Edmonton, Alberta, Canada. asr@ualberta.ca
authors.forename: Anthony S
authors.initials: AS
authors.lastname: Russell
authors.forename: Al
authors.initials: A
authors.lastname: Devani
authors.forename: Walter P
authors.initials: WP
authors.lastname: Maksymowych
mesh_terms: D000974:Antibodies, Antinuclear / Q000097:blood*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D042241:Early Diagnosis; D005455:Fluorescent Antibody Technique; D006801:Humans; D010456:Peptides, Cyclic / Q000097:blood / Q000276:immunology*; D011237:Predictive Value of Tests; D012219:Rheumatology / Q000379:methods*
chemical_list: D000974:Antibodies, Antinuclear; D015415:Biomarkers; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide